Double blind clinical trial in a series of 115 patients with seborrheic dermatitis: prevention of relapses using a topical modulator of Toll like receptor 2

Medicine and Dentistry

• Seborrheic Dermatitis 100%
• Toll Like Receptor 2 100%
• Inflammatory Disorder 66%
• Lipid 33%
• Innate Immunity 33%
• Species 33%
• Toll Like Receptor 33%
• Malassezia 33%
• Umbelliferone 33%
• Association 33%
• Skin 33%
• Patient 33%
• Relapse 33%
• Clinical Trial 33%
• Amaurosis 33%

Immunology and Microbiology

• Seborrhoeic Dermatitis 100%
• TLR2 100%
• Innate Immune System 33%
• Malassezia 33%
• Species 33%
• Association 33%
• Skin 33%
• Extract 33%